Department of Dermatology

Ex vivo expanded NK Cells from Melanoma Patients receive their Migration in a 3D Model and lyse autologous Melanoma Cells (2018) Rossner S, Czerwinski T, Mark C, Gross S, Karg M, Bosch JJ, Schuler-Thurner B, et al. Conference contribution Influence of previous Radiotherapy on the Success of an immune-oncologic Therapy in metastatic Melanoma - a retrospective multicenter Study of ADO (2018) Knispel S, Zimmer L, Gutzmer R, Heinzerling L, Weishaupt C, Pfoehler C, Gesierich A, et al. Conference contribution Extracellular Vesicles in the Plasma of Melanoma Patients under-press beta Catenin in Tumor Cells by using miRNA-34a (2018) Baur A, Lee JH, Dindorf J, Eberhardt M, Lai X, Ostalecki C, Koliha N, et al. Conference contribution Eosinophilic Fasciitis by Treatment with Checkpoint Inhibitors in metastatic Melanoma (2018) Toussaint F, Erdmann M, Moreira A, Kirchberger MC, Schuler G, Heinzerling L Conference contribution Expression of Senescence Markers - Is Predictive for Immune Therapy with Checkpoint Inhibitors? (2018) Moreira A, Gross S, Kirchberger MC, Erdmann M, Schuler G, Heinzerling L Conference contribution High volume of polysorbate-containing (Tween® 80) solutions induces false-positive results in intradermal test (2018) Wagner N, Podda M Journal article FV03 MEK Inhibitors improved the Survival of NRAS-mutated Melanoma Patients by using Checkpoint Inhibitors: Results of a retrospective, multicenter Analysis of 364 Patients (2018) Kirchberger MC, Ugurel S, Mangana J, Heppt M, Eigentler T, Berking C, Schadendorf D, et al. Conference contribution Fear of cancer progression in patients with stage IA malignant melanoma (2018) Wagner T, Augustin M, Blome C, Forschner A, Garbe C, Gutzmer R, Hauschild A, et al. Journal article Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry (2018) Worm M, Francuzik W, Renaudin JM, Bilo MB, Cardona V, Hofmeier KS, Kohli A, et al. Journal article From relative to absolute treatment outcomes-Correlation of PASI 90 and PASI <= 2 in three clinical trials with secukinumab (2018) Reich K, Bachhuber T, Melzer N, Sieder C, Sticherling M Conference contribution